Friedberg, Germany
Friedberg, Germany

Time filter

Source Type

Patent
Fresenius Kabi Deutschland GmbH | Date: 2016-12-12

Described herein are pharmaceutical packaging systems which prevent oxidative degradation of oxygen-sensitive drugs, such systems including a primary packaging container with an oxygen permeable component, a secondary packaging with very low permeability to oxygen and an oxygen absorber.


Patent
Fresenius Kabi Deutschland GmbH | Date: 2017-03-22

Provided herein, generally, are pharmaceutical formulations, e.g., injectable pharmaceutical formulations with improved stability, comprising morphine sulfate or a hydrate thereof, and methods of producing and using the same. Also provided herein are kits comprising the formulations, e.g., injectable morphine formulations.


Patent
Fresenius Kabi Deutschland GmbH | Date: 2016-07-27

The invention relates to a container closure system containing an overpouch with an intransparent first foil (10) and a transparent second foil (20), a transparent primary container (2) for holding a transparent pharmaceutical solution (3), wherein the transparent primary container (2) is packed within the overpouch (1) and labeled with at least one label (4) and wherein the at least one label (4) acts as a light absorbing segment having a reflection R_(L) for light in the range of 350 nm to 800 nm and an inner surface (18) of the intransparent first foil (10) of the overpouch (1) acts as a light reflecting background having a reflection R_(F) for light in the direction of the primary container (2) in the range of 350 nm to 800 nm with R_(F) > R_(L). By the transparent second foil (20) and the inventive reflection properties it is achieved that the at least one label (4) on the primary container (2) is visible and readable. Additionally, visual inspection of the content of the transparent primary container (2) is possible. A good contrast is achieved to enhance machine and human readability.


Patent
Fresenius Kabi Deutschland GmbH | Date: 2016-07-08

A syringe packaging system that includes a tube and a cap for enclosing a pre-filled syringe is disclosed. The tube includes a tube cut flange and the cap includes a cut skirt. With a syringe barrel contained within the tube, a syringe barrel cut flange is aligned with the tube cut flange. With the pre-filled syringe enclosed within the tube and the cap, the cut skirt of the cap surrounds the syringe barrel cut flange. In one embodiment, a film is securable to a portion of the tube and a portion of the cap to connect the tube and the cap with the pre-filled syringe enclosed within the cap and the tube.


Patent
Fresenius Kabi Deutschland GmbH | Date: 2016-07-08

A syringe packaging system including a shell for enclosing a pre-filled syringe is disclosed. The shell includes a first portion having a proximal end and a distal end having a disk-shaped bottom portion; and a second portion having a proximal end and a distal end. With the first portion engaged with the second portion to form the shell, the proximal end of the first portion and the proximal end of the second portion together define a syringe flange having a top wall that defines a shell proximal aperture, a bottom wall, and a sidewall.


Patent
Fresenius Kabi Deutschland GmbH | Date: 2015-01-28

Described herein are compositions for parenteral administration that include an aqueous phase and 5 to 30%, by weight, of an oil phase, based on the total weight of the composition. The oil phase comprises the omega-3 fatty acid ethylesters eicosapentaenoic acid ethylester, docosahexaenoic acid ethylester, and mixtures thereof. The composition further comprises at least one anionic surfactant and at least one amphoteric surfactant, and less than 0.05% by weight of oleic acid, based on the total weight of the composition. Also described is a method for preparing such a composition as well as such compositions for use as a medicament, in particular for use in treating stroke, sepsis, Alzheimers disease or cancer. Also featured are methods of treating these conditions by parenterally administering a composition to a patient in need thereof and methods of providing parenteral nutrition to such patients by administering to them a composition as described herein.


Patent
Fresenius Kabi Deutschland GmbH | Date: 2015-01-28

Described herein are compositions that include an aqueous phase and 5 to 30%, by weight, of an oil phase, based on the total weight of the composition. The oil phase comprises the omega-3 fatty acid triglyceride eicosapentaenoic acid triglyceride, docosahexaenoic acid triglyceride, or mixtures thereof. The composition further comprises at least one amphoteric surfactant, at least one co-surfactant, and at least one co-solvent. The compositions comprise less than 0.03% by weight of sodium oleate, based on the total weight of the composition. Also described are methods for preparing such compositions as well as such compositions for use as a medicament, in particular for use in treating stroke, sepsis, Alzheimers disease or cancer. Also featured are methods of treating these conditions by parenterally administering a composition to a patient in need and methods of providing parenteral nutrition to such patients by administering to them a composition as described herein.


Patent
Fresenius Kabi Deutschland GmbH | Date: 2015-12-03

The present invention relates to hydroxyalkyl starch or a pharmaceutical preparation thereof for the treatment of cancer, tumor or tumor associated diseases, especially by effectively reducing tumor growth rate and inhibiting tumor growth and wherein the hydroxyalkyl starch has a mean molecular weight (MW) above 20 and below 1300 kDa and a molar substitution (MS) in the range of from 0.1 to 1.5, wherein the alkylation may be an ethylation, propylation or butylation or mixes thereof; and wherein the alkyl may be further substituted.


The invention relates to a composition comprising a combination of the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The composition can be used for enhancing the activity of chemotherapy or radiotherapy and/or in the prevention or reduction of side effects caused by the chemotherapy or radiotherapy in a patient ill with cancer, the composition being intended for administration to the patient prior to the commencement of a cycle of chemotherapy or radiotherapy.


Patent
Fresenius Kabi Deutschland GmbH | Date: 2015-07-13

The invention relates to a connector for containers containing medicinal active ingredient, which connector makes it possible to transfer active ingredient from one container into another container. The connector (1, 1) according to the invention comprises a first connection region (3, 3) for the connection of a first container (2, 2), a guide element (4, 4), a piercing element (5, 5) and a partition wall (6), wherein the guide element (4, 4) has a duct (7) designed for transferring a medicinal active ingredient, the piercing element (5, 5) is arranged, at least in certain sections, in the duct (7) and is axially movably guided within the duct (7) by the guide element (4, 4), and, by connecting a container (2, 2) in the first connection region (3, 3), the piercing element (5, 5) can be moved from a starting position, in which the piercing element (5, 5) does not open the partition wall (6), into an end position, in which the piercing element (5, 5) opens the partition wall (6) in order to transfer a medicinal active ingredient.

Loading Fresenius Kabi Deutschland GmbH collaborators
Loading Fresenius Kabi Deutschland GmbH collaborators